HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cardiovascular Risk Stratification of Patients Undergoing Hematopoietic Stem Cell Transplantation: The CARE-BMT Risk Score.

AbstractBACKGROUND:
Evidence guiding the pre-hematopoietic stem cell transplantation (HSCT) cardiovascular evaluation is limited. We sought to derive and validate a pre-HSCT score for the cardiovascular risk stratification of HSCT candidates.
METHODS AND RESULTS:
We leveraged the CARE-BMT (Cardiovascular Registry in Bone Marrow Transplantation) study, a contemporary multicenter observational study of adult patients who underwent autologous or allogeneic HSCT between 2008 and 2019 (N=2435; mean age at transplant of 55 years; 4.9% Black). We identified the subset of variables most predictive of post-HSCT cardiovascular events, defined as a composite of cardiovascular death, myocardial infarction, heart failure, stroke, atrial fibrillation or flutter, and sustained ventricular tachycardia. We then developed a point-based risk score using the hazard ratios obtained from Cox proportional hazards modeling. The score was externally validated in a separate cohort of 919 HSCT recipients (mean age at transplant 54 years; 20.4% Black). The risk score included age, transplant type, race, coronary artery disease, heart failure, peripheral artery disease, creatinine, triglycerides, and prior anthracycline dose. Risk scores were grouped as low-, intermediate-, and high-risk, with the 5-year cumulative incidence of cardiovascular events being 4.0%, 10.3%, and 22.4%, respectively. The area under the receiver operating curves for predicting cardiovascular events at 100 days, 5 and 10 years post-HSCT were 0.65 (95% CI, 0.59-0.70), 0.73 (95% CI, 0.69-0.76), and 0.76 (95% CI, 0.69-0.81), respectively. The model performed equally well in autologous and allogeneic recipients, as well as in the validation cohort.
CONCLUSIONS:
The CARE-BMT risk score is easy to calculate and could help guide referrals of high-risk HSCT recipients to cardiovascular specialists before transplant and guide long-term monitoring.
AuthorsAlexi Vasbinder, Tonimarie Catalan, Elizabeth Anderson, Catherine Chu, Megan Kotzin, Danielle Murphy, Halle Cheplowitz, Kristen Machado Diaz, Brayden Bitterman, Ian Pizzo, Yiyuan Huang, Jeffrey Xie, Christopher W Hoeger, Rayan Kaakati, Hanna P Berlin, Husam Shadid, Daniel Perry, Michael Pan, Radhika Takiar, Kishan Padalia, Jamie Mills, Chelsea Meloche, Alina Bardwell, Matthew Rochlen, Pennelope Blakely, Monika Leja, Mousumi Banerjee, Mary Riwes, John Magenau, Sarah Anand, Monalisa Ghosh, Attaphol Pawarode, Gregory Yanik, Sunita Nathan, John Maciejewski, Tochukwu Okwuosa, Salim S Hayek
JournalJournal of the American Heart Association (J Am Heart Assoc) Vol. 13 Issue 1 Pg. e033599 (Jan 02 2024) ISSN: 2047-9980 [Electronic] England
PMID38158222 (Publication Type: Observational Study, Multicenter Study, Journal Article)
Topics
  • Adult
  • Humans
  • Middle Aged
  • Bone Marrow Transplantation (adverse effects)
  • Risk Factors
  • Cardiovascular Diseases (diagnosis, epidemiology, etiology)
  • Hematopoietic Stem Cell Transplantation (adverse effects)
  • Heart Failure (epidemiology, therapy, complications)
  • Retrospective Studies

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: